Risk stratification guidelines for AML have been drawn up by several organizations, including the World Health Organization (WHO), the National Comprehensive Cancer Network (NCCN), and the European Leukemia Network (ELN) [19,52], specifying that the presence of FLT3-ITD is a genetic alteration that identifies a well-defined subgroup of patients. Here, FLT3 is linked to acute myeloid leukemia.